Press Release

No results
Press Release
COVID-19
Delta
Life Science Alliance
Omicron
Plitidepsin
January 11, 2022

Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants

PharmaMar (MSE:PHM) has announced today the publication of an article in the Life Science Alliance journal, entitled "Pre-clinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19," which includes a study on the in vitro activity of plitidepsin against the main SARS-CoV-2 variants, including the current Omicron variant.

Press Release
Eczacibasi
lurbinectedin
Turkey
December 22, 2021

PharmaMar signs a new licensing and commercialization agreement with Eczacibasi for lurbinectedin in Turkey

PharmaMar (MSE:PHM) has announced today a new license and commercialization agreement with the Eczacıbaşı Pharmaceuticals Marketing Co. to commercialize the anticancer drug lurbinectedin in Turkey.

Press Release
appointment
Communication Director
December 14, 2021

PharmaMar appoints Lara Vadillo as Communication Director

PharmaMar (MSE:PHM) has appointed Lara Vadillo to lead the Company's Communication Department.

Press Release
Jazz Pharmaceuticals
lurbinectedin
Small Cell Lung Cancer
Zepzelca®
December 13, 2021

PharmaMar and Jazz Pharmaceuticals announce initiation of confirmatory phase III clinical trial of Zepzelca® (lurbinectedin) for the treatment of patients with relapsed Small Cell Lung Cancer

PharmaMar (MSE:PHM) and partner Jazz Pharmaceuticals plc (Nasdaq:JAZZ) today announced the initiation of a confirmatory Phase III clinical trial, LAGOON, evaluating Zepzelca® (lurbinectedin) for the treatment of patients with relapsed Small Cell Lung Cancer (SCLC).

Press Release
December 9, 2021

PharmaMar launches its new corporate website

PharmaMar (MSE:PHM) has published today its new corporate website, with a revamped design and new functionalities. This new website represents what this company is today, a unique company with more than 30 years of successful history, three approved products and a promising future.

Press Release
Lotus Pharmaceutical
lurbinectedin
Taiwan
November 11, 2021

PharmaMar signs a licensing and commercialization agreement with Lotus Pharmaceutical for lurbinectedin in Taiwan

PharmaMar S.A. (MSE:PHM) has announced today a licensing agreement with Lotus Pharmaceutical CO., LTD. (TWSE:1795) to commercialize the anticancer drug lurbinectedin in Taiwan.

Loading
Load more
0.3484 seconds.